Skip to main content
Premium Trial:

Request an Annual Quote

Court Dismisses Enzo's IP-Infringement Suit Against ABI

NEW YORK (GenomeWeb News) — A US District Court in Connecticut has dismissed Enzo Biochem’s patent-infringement suit against Applied Biosystems by granting ABI’s motion for a summary judgment, ABI said today.
 
In the lawsuit, filed in 2004, Enzo and co-plaintiff Yale University alleged that ABI infringes six patents covering methods for modifying, preparing, and labeling nucleotides. Four of the patents were assigned to Yale and two were assigned to Enzo Life Sciences.
  
Specifically, Enzo and Yale said ABI’s sequencing reagent kits, its Taqman genotyping and gene expression assays, and its gene-expression microarrays infringe on Yale’s US Patent Nos. 4,476,928; 5,449,767; 5,328,824; and 4,711,955, and Enzo’s US Patent Nos. 5,082,830 and 4,994,373.
 
Enzo and Yale had sought monetary damages, costs, injunctions and other relief from the court.
 
Enzo said in a statement released this morning that it has filed a notice of appeal with the Court of Appeals for the Federal Circuit.
 
"While disappointing, we believe that the ruling is not reflective of the facts in the case and it certainly does not impact our intellectual property portfolio of more than 200 patents," Enzo President Barry Weiner said in the statement.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.